Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mutabilis Receives EUR Four Million of EU Funding for its HIVINNOV Project

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
HIVINNOV was ranked second out of 24 projects retained after a request for HIV, malaria and tuberculosis projects under the EU’s FP7 2012 health research program.

Mutabilis has announced that it has received EUR four million of European funding for the HIVINNOV project, which is aimed at developing new antiretrovirals against HIV.

The Mutabilis project, known as “Generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions”, or HIVINNOV, entails the development of new anti-HIV antiretrovirals up to the Phase IIa clinical trial stage.

The particular feature of these new antiretrovirals is that they do not target the virus directly, as the majority of existing antiretrovirals do, but the interactions between the virus and its host, which are essential for the replication of the virus.

The project, which will get under way in October when a launch meeting is to be held at the Biocitech science and technology park, is due to last three years and to receive total funding of EUR six million.

Mutabilis, which is the coordinator of the project as well as a partner in it, formed a consortium in July 2011 comprising five prestigious European academic research establishments that are regarded as world leaders in the field of virus-host cell interactions in the area of HIV.

They are the following: University College London (UCL) and the Cancer Research Institute UK (CRUK) in the United Kingdom; the Academic Medical Center of the University of Amsterdam (AMC) in the Netherlands; the AIDS Units Clinical Institute of the University of Barcelona (FCRB) in Spain and a group of two French research establishments - the Institut Cochin, which is run jointly by the National Institute of Health and Medical Research (INSERM), the National Scientific Research Center (CNRS) and the University of Paris Descartes) and the University Hematology Institute (IUH) of the Saint Louis Hospital in Paris (run by INSERM, the CNRS and the University of Paris Diderot).

Of the 1,135 projects submitted under the FP7 2012 health research program, which spawned the request for proposals to which Mutabilis responded, 319 were short-listed in the first instance (on the basis of program summaries), after which 121 were finally selected, representing a success rate of around ten per cent.

The European Union’s seventh framework program (FP7), which has been allotted a total budget of EUR 50.5 billion for the 2007-2013 period, brings together all the EU’s research initiatives under one roof and plays an important role in achieving its growth, competitiveness and employment targets.

A budget of EUR 6.05 billion has been assigned to cooperation in human health. HIVINNOV was selected from among research programs aimed at discovering innovative drugs and developing vaccines against the infectious and parasitic diseases responsible for the world’s worst human health problems, which affect poorer countries in particular, although not exclusively, namely malaria, tuberculosis and HIV infection, which is responsible for AIDS.

“The commission was apparently very impressed with the major advances we have made with the compounds we are developing, as well as the quality of the consortium and the research projects proposed,” said the scientific director of Mutabilis, Dr. Richard Benarous.

Dr. Benarous continued, “This success should encourage all the companies on the Biocitech campus to pay more attention and respond to European tenders that often give precedence to collaborations between innovative SMEs and European academic partners.”

“The funding secured for the research program coordinated by Mutabilis is very good news in a difficult economic climate,” added the president of Biocitech, Jean-François Boussard.

Boussard continued, “It shows that the companies installed at Biocitech implement ambitious development programs, collaborate with the best European research teams and thereby contribute to spreading the word about Biocitech and the Paris basin ecosystem.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biocitech Welcomes Helios BioSciences to its Technology Park
Helios identifies therapeutic targets and biomarkers using its proprietary technology platform for predicting molecular interactions.
Wednesday, March 07, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!